A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

What this study is about

This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).

Who can join (things the study team will check)

✅ You may be able to join if…

• Patients aged ≥ 18 years at time of study entry.
• Patients have histologically confirmed RCC with clear cell component.
• Patients have locally advanced and unresectable or metastatic disease.
• Measurable disease as assessed only by the investigator (not verified by IRC) according to RECIST version 1.1.
• Patients must not have had any prior vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor treatment in either (neo)adjuvant or locally advanced/metastatic setting. Up to 1 line of prior cytokine or immune checkpoint inhibitor treatment is allowed in either the (neo)adjuvant or metastatic setting provided screening scans indicate progressive disease (PD) during or following completion of treatment.
• Patients have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Patients have adequate baseline organ function.
• Patients have adequate baseline hematologic function
• Patient must be at least 2 weeks from last systemic treatment or dose of radiation prior to date of randomization.

🚫 You may not be able to join if…

• Has persistent clinically significant toxicities (Grade ≥ 2; per NCI CTCAE version 5 from previous anticancer therapy (excluding alopecia which is permitted and excluding Grades 2 and 3 laboratory abnormalities if they are not associated with symptoms, are not considered clinically significant by the investigator, and can be managed with available medical therapies).
• Has untreated central nervous system (CNS) metastases. Patients with treated CNS metastases are eligible provided imaging demonstrates no new or progressive metastases obtained at least 4 weeks following completion of treatment. CNS imaging during Screening is not required unless clinically indicated.
• Has an additional malignancy requiring treatment within the past 3 years. Patients with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ, and non-muscle invasive urothelial carcinoma.
• Poorly controlled hypertension, defined as systolic blood pressure ≥ 160 or diastolic blood pressure ≥ 100 mmHg. Use of anti-hypertensives and rescreening is permitted.
• A new pulmonary embolism or deep venous thrombosis diagnosed within 3 months prior to randomization.
• Has a QTcF interval > 480 msec.
• New York Heart Association Class III or IV congestive heart failure.
• Use of prohibited medication within 7 days or 5 half-lives, whichever is shorter, prior to first dose of study drug.

Where this trial is running

• University Of UA Cancer Center(UACC)/DH-SJHMC, Phoenix, Arizona, United States
• University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
• UCSF Helen Diller Family Comphrensive Cancer Center - Hemato, San Francisco, California, United States
• Norton Cancer Institute, Norton Healthcare Pavilion, Louisville, Kentucky, United States
• Ochsner Clinic Foundation, New Orleans, Louisiana, United States
• GU Research Network/Urology Cancer Center, Omaha, Nebraska, United States
• Nebraska Cancer Specialists, Omaha, Nebraska, United States
• Northwell Health/Monter Cancer Center, Lake Success, New York, United States
• Mainstreet Physicans Care, Rochester, New York, United States
• Precision Cancer Research/Dayton Physicians Network - Treatment, Kettering, Ohio, United States
• Oregon Health and Science University, Portland, Oregon, United States
• St. Luke's Hospital, Easton, Pennsylvania, United States

+ 26 more sites.

Who to contact

Sophia Paspal, Ph.D. · 6104055974 · sophia.paspal@xynomicpharma.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT03592472.